Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib
Hua Cheng(Guangdong General Hospital), Yi‐Long Wu(Guangdong General Hospital)
Cited by 33
Related Papers
Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status
|Journal of Hematology & Oncology|2015|89
The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC
|Journal of Thoracic Oncology|2016|67
miR-144-3p, a tumor suppressive microRNA targeting ETS-1 in laryngeal squamous cell carcinoma
|Oncotarget|2016|43
Combinations of laminin 5 with PTEN, p-EGFR and p-Akt define a group of distinct molecular subsets indicative of poor prognosis in patients with non-small cell lung cancer
|Experimental and Therapeutic Medicine|2012|14